TCM
SGMO

Teza Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Teza Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,987
Closed -$37K – 573
2016
Q4 		$37K Buy
+11,987
New +$43.6K 0.05% 228

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

Teza Capital Management's SGMO Position: Q1 2017 in Review

Teza Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2017, closing a stake of 11,987 shares — an estimated $37K sold.

Teza Capital Management first reported a position in SGMO in Q4 2016 and held it in 1 quarter. The position peaked at $37K in Q4 2016. 118 funds tracked by Wall St. Rank hold SGMO as of Q1 2017.

  • Teza Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 11,987 SANGAMO THERAPEUTICS INC shares in Q1 2017, an estimated $37K.
  • Teza Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's SANGAMO THERAPEUTICS INC position peaked at $37K in Q4 2016.
  • 118 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.